• Core Scientific (NasdaqGS:CORZ) has secured a $500 million loan facility from Morgan Stanley.
• The facility is intended to support the company’s shift from Bitcoin mining to AI and high performance computing data center services.
• The financing has the potential to increase to $1 billion, expanding available capital for data center development.

Core Scientific, trading at $14.86, is using this new funding to support a clear change in its business model. The stock has seen a 91.0% return over the past year, while shorter term returns over 7 days, 30 days, and year to date have been negative. This combination of recent pressure and stronger 1-year performance provides context as the company allocates more resources to AI and HPC services.

For investors, an important question is how effectively Core Scientific can convert this $500 million facility, and any potential expansion to $1 billion, into income-producing data center capacity. The shift away from pure Bitcoin mining toward AI and HPC colocation could affect its revenue profile and risk exposure over time, so future updates on the deployment of this capital and customer traction will be important to monitor.

Stay updated on the most important news stories for Core Scientific by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Core Scientific.

The Morgan Stanley facility gives Core Scientific short term access to up to US$500 million of debt capital, potentially rising to US$1 billion if the accordion feature is used. With a 364 day term and a floating rate of SOFR plus 2.50%, this is relatively expensive, short dated funding that increases interest costs and refinancing risk if cash flows from AI and HPC data centers do not ramp quickly. At the same time, the company has just reported full year 2025 revenue of US$319.02 million and a net loss of US$288.62 million, so adding leverage on top of loss making operations raises questions about future debt servicing capacity and debt to equity metrics, especially given flagged weaknesses in internal controls and recent financial restatements.

How This Fits Into The Core Scientific Narrative

• The facility directly supports the narrative that reallocating capital from Bitcoin mining to HPC infrastructure can build a power rich data center portfolio that serves AI and compute intensive clients over time.
• Using a short term loan while the business is still loss making could challenge the narrative if execution delays, customer ramp issues, or concentration around contracts like CoreWeave limit cash generation before the debt matures.
• The narrative focuses heavily on equity funded growth and earlier debt restructuring, while this new SOFR linked loan and potential US$1 billion commitment add fresh refinancing risk that is not fully reflected in that story.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Core Scientific to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Additional short term debt at SOFR plus 2.50% increases interest expense and refinancing risk for a company that reported a full year 2025 net loss of US$288.62 million and has less than one year of cash runway.
• ⚠️ Material weaknesses in internal controls, financial restatements, and negative shareholders' equity, as flagged in risk checks, add governance and balance sheet concerns just as leverage rises.
• 🎁 The facility gives Core Scientific greater financial flexibility to progress AI and HPC data center projects, including power expansions in Texas and Georgia that support its colocation pivot.
• 🎁 Access to up to US$1 billion of debt capacity, alongside proceeds from Bitcoin sales, offers funding optionality to build out its 1.5 gigawatt hosting pipeline, competing with data center and AI compute peers such as Marathon Digital, Riot Platforms, and Hut 8 that are also repositioning their asset bases.

What To Watch Going Forward

From here, you will want to watch how quickly Core Scientific draws on the facility, the exact mix of projects funded, and any new disclosures around debt covenants or future refinancing plans when the 364 day term comes due. Monitoring quarterly cash flow, interest expense, and net leverage alongside progress on AI and HPC customer contracts, including the pace of CoreWeave ramp and new client wins, will be important. Given the recent restatement and internal control issues, future filings and audit commentary will also matter for assessing financial reporting quality. To ensure you're always in the loop on how the latest news impacts the investment narrative for Core Scientific, head to the community page for Core Scientific to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.